Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: A preliminary study

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1286-1297

  Chen, Hong ^a   Song, Zhenju ^a   Qian, Mengjia ^a   Bai, Chunxue ^a   Wang, Xiangdong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AECOPD; Biomarkers; Clinical informatics; COPD; Inflammation

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CHEMOKINE;

AGED; ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; FEMALE; HUMAN; INFLAMMATION; MALE; MEDICAL INFORMATICS; PATHOPHYSIOLOGY; PROTEOMICS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEMOKINES; CLUSTER ANALYSIS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MEDICAL INFORMATICS; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84861559991     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01416.x     Document Type: Article

References (36)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-46.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004; 364: 613-20.
3. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011; 139: 920-9.
4. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J. 2003; 22: 931-6.
5. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163: 1256-76.
6. Hurst JR, Wedzicha JA. Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation. Postgrad Med J. 2004; 80: 497-505.
7. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174: 867-74.
8. Sapey E, Stockley RA. COPD exacerbations. 2: Aetiology. Thorax. 2006; 61: 250-8.
9. Wouters EF, Groenewegen KH, Dentener MA, et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007; 4: 626-34.
10. He Z, Chen Y, Chen P, et al. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology. 2010; 15: 478-84.
11. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007; 131: 37-43.
12. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000; 84: 210-5.
13. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007; 62: 595-601.
14. Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J. 2010; 35: 540-8.
15. Kato H, Nishimura T, Ikeda N, et al. Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics. 2011; 74: 759-64.
16. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010; 137: 1410-6.
17. Shen Y, Wang Y, Chen Z, et al. Role of aquaporin 5 in antigen-induced airway inflammation and mucous hyperproduction in mice. J Cell Mol Med. 2011; 15: 1355-63.
18. Zhang Y, Wang L, Zhang M, et al. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Atk-Erk pathway. J Cell Physiol. 2011; doi: 10.1002/jcp.22722.
19. Chen H, Wang D, Bai C, et al. Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res. 2010; 9: 2798-808.
20. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond). 2008; 115: 225-32.
21. Bon JM, Leader JK, Weissfeld JL, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One. 2009; 4: e6865.
22. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996; 51: 819-24.
23. Kythreotis P, Kokkini A, Avgeropoulou S, et al. Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2009; 9: 1-10.
24. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59: 574-80.
25. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med. 2009; 103: 1548-53.
26. de Torres JP, Casanova C, Pinto-Plata V, et al. Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. PLoS One. 2011; 6: e16021.
27. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 1999; 20: 254-7.
28. Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003; 4: 1-8.
29. Liu SF, Chin CH, Wang CC, et al. Correlation between serum biomarkers and BODE index in patients with stable COPD. Respirology. 2009; 14: 999-1004.
30. Ray CA, Bowsher RR, Smith WC, et al. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal. 2005; 36: 1037-44.
31. Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods. 2006; 38: 317-23.
32. Trune DR, Larrain BE, Hausman FA, et al. Simultaneous measurement of multiple ear proteins with multiplex ELISA assays. Hear Res. 2010; 275: 1-7.
33. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12.
34. Wang X, Adler KB, Chaudry IH, et al. Better understanding of organ dysfunction requires proteomic involvement. J Proteome Res. 2006; 5: 1060-2.
35. Riva A, Nuzzo A, Stefanelli M, et al. An automated reasoning framework for translational research. J Biomed Inform. 2010; 43: 419-27.
36. Celli BR. Predictors of mortality in COPD. Respir Med. 2010; 104: 773-9.